Compare M&T Bank Corporation (MTB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Sana Biotechnology Inc — how do they compare? M&T Bank Corporation trades at $252.44 (market cap $36.42B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: M&T Bank Corporation is far larger — about 32.2× Sana Biotechnology Inc's market cap, and M&T Bank Corporation pays a 2.38% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MTB | SANA | |
|---|---|---|
Market Cap | $36.42B | $1.13B |
Sector | Financials | Health |
52-Week High | $254.04 | $5.92 |
52-Week Low | $178.63 | $2.68 |
Dividend Yield | 2.38% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $251.13, up 0.27% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows consistent revenue growth, with 2025 revenue at $9.63B and net income margin of 29.59%, supported by a P/E of 13.35. Analyst consensus is a Hold with a $255.92 price target, while recent news highlights robust Q2 2026 results and dividend stability.
Outlook remains positive due to earnings momentum and loan growth, but risks include rising costs and macroeconomic pressures. The stock offers value with a reasonable valuation and dividend yield, though investor caution is warranted amid mixed analyst ratings and net cash flow challenges.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
